Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10014

Result Summary for APV10014

Result Summary

Protocol ID:	APV10014
Clinical Study ID:	APV10014
Official Title:	A Phase I, Open Label, Single Arm, Three Period, Drug-Drug Interaction Study to Assess the Steady-State Plasma Amprenavir and Nevirapine Pharmacokinetics Following Administration of GW433908 1400mg BID + Nevirapine 200mg BID for 14 days and GW433908 700 mg BID + Nevirapine 200mg BID + Ritonavir ...
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	Telzer,Telzir,Lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	E. DeJesus, P. Piliero, K. Summers, M.J. Shelton, M.B. Wire, Y. Lou, A. Masterman, D.S. Stein. Evaluation of the Pharmacokinetic Drug Interaction between Fosamprenavir (FPV), FPV plus Ritonavir (RTV), and Nevirapine (NVP) in HIV-Infected Patients (APV10014). 44th ICAAC, 10/30/2004 Washington, DC; USA